Momentum Clinical Research at IDWeek 2026

Oct 21–24, 2026 Washington, DC ~12k attendees Website

Momentum Clinical Research brings 2 presentations to IDWeek 2026 in Washington. Its program centres on an early-stage trial for recurrent genital herpes. It reports interim efficacy and virologic results for an oral, long-acting helicase-primase inhibitor against herpes simplex virus.

OrganizationIDWeek 2026 Attendance
momentumclinicalresearch.com
Services & software
Network of clinical trial sites across New Zealand and Australia, including a site on the Kapiti Coast.
Talk
Fri Oct 23
12:35pm–12:40pm
Part of Rapid-Fire Poster Session: Old Foes, New Strategies
Efficacy and Virologic Analyses of GS-1179, a Novel, Oral, Long-Acting HSV Helicase-Primase Inhibitor for Recurrent Genital Herpes: Interim Results from a Phase 1b Study
RF Arena 2
Transplant and immunocompromised hosts
Poster
Sat Oct 24
12:15pm–1:30pm
Efficacy and Virologic Analyses of GS-1179, a Novel, Oral, Long-Acting HSV Helicase-Primase Inhibitor for Recurrent Genital Herpes: Interim Results from a Phase 1b Study
Poster Hall B-C · Poster P-2052
V3. Studies of treatment and prevention of viral infections

Explore the full IDWeek 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Washington. Leave your work email and we’ll be in touch.

Privacy

Download the full IDWeek 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Momentum Clinical Research

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction